Amphastar Pharmaceuticals saw a 9% decrease in its shares, dropping to $46.97, following the announcement of its plans to offer $300 million of convertible senior notes due 2029 in a private placement.
Positive Growth for Amphastar
Despite the recent decline, it is worth noting that Amphastar Pharmaceuticals experienced a significant surge in its stock price, reaching a 52-week high of $67.66 on August 9. Over the past year, the shares have increased by an impressive 62%.
Additional Option for Purchasers
As part of the offering, Amphastar intends to grant the initial purchasers of the notes an option to purchase up to an additional $45 million in notes.
Key Details of the Notes
The convertible senior notes will represent general senior unsecured obligations of Amphastar and will accrue interest payable semi-annually in arrears. The specific interest rate, initial conversion rate, and other terms will be determined at the time of pricing for the offering.
Allocation of Proceeds
Amphastar plans to utilize $200 million from the offering to repay its existing term loan borrowings. Furthermore, they anticipate using up to $50 million to repurchase their own stock. The remaining proceeds will be allocated towards general corporate purposes.